Clinical Trial Update: A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL [Phase 1, Phase 2]

View source ↗

Summary

A dose-ranging study of IV BNZ-1 in LGL Leukemia or refractory cutaneous T-cell lymphoma (CTCL) has completed Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Lgl Leukemia

Drugs mentioned

• BNZ-1

Snippet

Sponsor: Bioniz Therapeutics | Conditions: LGL Leukemia, CTCL | Phase 1, Phase 2 | Status: COMPLETED